Renal allograft outcome in the cyclosporine era: comparison between intermediate-term failure and long-term survival.
A single center experience of 160 cyclosporine-treated renal allografts that survived longer than 1 year was reviewed in an attempt to analyze the contribution of selected parameters to long-term survival. Sixty-one grafts were lost between 1 and 5 years, with the remaining functioning for longer than 5 years. Parameters with a significant influence on long-term survival included both quality of early graft function, with 13% of long-term survivors having delayed function, compared to 52% among the short-term survival group, and the incidence of acute rejection in the first year posttransplant (31% in long-term survivors compared to 63% in the short-term survival group). A marker for long-term survival (greater than 5 years) was a lower serum creatinine at 1 year (1.9 +/- 0.1 mg/dl, compared with 2.6 +/- 0.2 mg/dl in the short-term survival group). Recipient race, original renal disease, number of transplants and/or transfusions, panel reactive antibodies, and human leukocyte antigens matching did not appear to influence long-term outcome.
Sumrani
N
N
Department of Surgery, State University of New York Health Science Center, Brooklyn 11203.
Delaney
V
V
Hong
J H
JH
Daskalakis
P
P
Friedman
E A
EA
Sommer
B G
BG
D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D015994:Incidence; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D012307:Risk Factors; D013997:Time Factors
D016572:Cyclosporine